Displaying all 2 publications

Abstract:
Sort:
  1. Mohammadzadeh N, Gholamzadeh M, Saeedi S, Rezayi S
    J Ambient Intell Humaniz Comput, 2023;14(5):6027-6041.
    PMID: 33224305 DOI: 10.1007/s12652-020-02656-x
    Wearable smart sensors are emerging technology for daily monitoring of vital signs with the reducing discomfort and interference with normal human activities. The main objective of this study was to review the applied wearable smart sensors for disease control and vital signs monitoring in epidemics outbreaks. A comprehensive search was conducted in Web of Science, Scopus, IEEE Library, PubMed and Google Scholar databases to identify relevant studies published until June 2, 2020. Main extracted specifications for each paper are publication details, type of sensor, disease, type of monitored vital sign, function and usage. Of 277 articles, 11 studies were eligible for criteria. 36% of papers were published in 2020. Articles were published in 10 different journals and only in the Journal of Medical Systems more than one article was published. Most sensors were used to monitor body temperature, heart rate and blood pressure. Wearable devices (like a helmet, watch, or cuff) and body area network sensors were popular types which can be used monitoring vital signs for epidemic trending. 65% of total papers (n = 6) were conducted by the USA, Malaysia and India. Applying appropriate technological solutions could improve control and management of epidemic disease as well as the application of sensors for continuous monitoring of vital signs. However, further studies are needed to investigate the real effects of these sensors and their effectiveness.
  2. Nguyen TN, Qureshi MM, Klein P, Yamagami H, Abdalkader M, Mikulik R, et al.
    J Stroke, 2022 May;24(2):256-265.
    PMID: 35677980 DOI: 10.5853/jos.2022.00752
    BACKGROUND AND PURPOSE: Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year.

    METHODS: We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020).

    RESULTS: There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths.

    CONCLUSIONS: During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT.

Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links